Fuxing Zuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fuxing Zuo has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Hongyan Han
Department of Neurosurgery, Aviation General Hospital, Beijing, China; and
2 shared publications - Jinghai Wan
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2 shared publications - Cheng Fang
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication - Guangtao Zhang
Department of Neurosurgery, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China
1 shared publication Guoqiang Chen
1 shared publicationHaipeng Qian
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication
Latest Publications
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e214952
Medullary Edema Due to Dural Arteriovenous Fistulas With Contralateral Drainage Through the Transverse Pontine Vein
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e214952
Medullary Edema Due to Dural Arteriovenous Fistulas With Contralateral Drainage Through the Transverse Pontine Vein
- Open Access
- 18 September 2026
- Published by Elsevier in World Neurosurgery: X
- Vol. 32
One-stage tumor resection and revascularization for moyamoya vasculopathy coexisting with meningioma: A case series and technical considerations
- 18 September 2026
- Published by Elsevier in World Neurosurgery: X
- Vol. 32
Open AccessOne-stage tumor resection and revascularization for moyamoya vasculopathy coexisting with meningioma: A case series and technical considerations
- Open Access
- 1 April 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (2)
Regulatory mechanisms of O6-methylguanine methyltransferase expression in glioma cells
O6-methylguanine methyltransferase (MGMT), a pivotal DNA repair enzyme, has its dysregulation playing a substantial role in gliomagenesis, the development of therapeutic resistance, and patient prognosis. This narrative review is designed to offer an all-encompassing overview of the intricate regulatory mechanisms that govern MGMT expression in glioma cells. We systematically investigate the diverse levels of regulation that impact MGMT expression in glioma. These include epigenetic regulation, transcriptional control, post-translational modifications, and the influence exerted by the tumor microenvironment. Epigenetically, methylation of CpG islands within the MGMT promoter region represents a critical determinant for gene silencing. Conversely, histone modifications such as H3K4me3 augment MGMT expression. Transcriptionally, a complex network of transcription factors, which encompasses Sp1, p53, and NF-κB, along with signaling pathways like TGF-β, JAK/STAT, and PI3K/AKT, orchestrates MGMT expression in glioma cells. Furthermore, post-translational modifications of MGMT, such as phosphorylation and ubiquitination, are of pivotal importance in modulating its stability and enzymatic activity. The tumor microenvironment, with factors such as oxidative stress, hypoxia, and immune responses, also exerts a significant influence on MGMT expression. This narrative review delves deeper into the relationship between MGMT expression and drug resistance, especially resistance to alkylating chemotherapy agents, and accentuates the significance of evaluating MGMT expression for personalized glioma therapy. By elucidating these regulatory mechanisms, this review endeavors to enhance our understanding of MGMT's role in glioma biology and to provide insights for future therapeutic strategies aimed at surmounting current treatment challenges.
- 1 April 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (2)
Open AccessRegulatory mechanisms of O6-methylguanine methyltransferase expression in glioma cells
O6-methylguanine methyltransferase (MGMT), a pivotal DNA repair enzyme, has its dysregulation playing a substantial role in gliomagenesis, the development of therapeutic resistance, and patient prognosis. This narrative review is designed to offer an all-encompassing overview of the intricate regulatory mechanisms that govern MGMT expression in glioma cells. We systematically investigate the diverse levels of regulation that impact MGMT expression in glioma. These include epigenetic regulation, transcriptional control, post-translational modifications, and the influence exerted by the tumor microenvironment. Epigenetically, methylation of CpG islands within the MGMT promoter region represents a critical determinant for gene silencing. Conversely, histone modifications such as H3K4me3 augment MGMT expression. Transcriptionally, a complex network of transcription factors, which encompasses Sp1, p53, and NF-κB, along with signaling pathways like TGF-β, JAK/STAT, and PI3K/AKT, orchestrates MGMT expression in glioma cells. Furthermore, post-translational modifications of MGMT, such as phosphorylation and ubiquitination, are of pivotal importance in modulating its stability and enzymatic activity. The tumor microenvironment, with factors such as oxidative stress, hypoxia, and immune responses, also exerts a significant influence on MGMT expression. This narrative review delves deeper into the relationship between MGMT expression and drug resistance, especially resistance to alkylating chemotherapy agents, and accentuates the significance of evaluating MGMT expression for personalized glioma therapy. By elucidating these regulatory mechanisms, this review endeavors to enhance our understanding of MGMT's role in glioma biology and to provide insights for future therapeutic strategies aimed at surmounting current treatment challenges.
- 9 July 2022
- Published by Elsevier in World Neurosurgery
- Vol. 166, e337-e344
Maxillary Swing Approach for Central Skull Base Lesions in Extreme Situations: A Single-Institutional Case Series
- 9 July 2022
- Published by Elsevier in World Neurosurgery
- Vol. 166, e337-e344
Maxillary Swing Approach for Central Skull Base Lesions in Extreme Situations: A Single-Institutional Case Series